[MK TEST DO NOT TOUCH] The 2024 American Academy of Dermatology (AAD) Annual Meeting

San Diego, California, US 08 March 2024 - 12 March 2024

Upadacitinib increases time spent with improved AD-related symptoms

26 Mar 2024 by

Treatment with upadacitinib, an oral selective Janus kinase inhibitor, led to greater proportions of days spent with improved nighttime itch and sleep disturbance experienced by patients with moderate-to-severe atopic dermatitis (AD), according to an integrated analysis of the phase III Measure Up 1 and 2 studies presented at AAD 2024.

Upadacitinib increases time spent with improved AD-related symptoms

26 Mar 2024

Lebrikizumab plus TCS improves outcomes in moderate-to-severe AD

23 Mar 2024 by

Treatment with lebrikizumab in combination with topical corticosteroids (TCS), compared with TCS alone, results in early and sustained improvements in patient-reported outcomes (PROs) among individuals with moderate-to-severe atopic dermatitis (AD), as shown in a Japan study.

Lebrikizumab plus TCS improves outcomes in moderate-to-severe AD

23 Mar 2024

Injectable polidocanol targets double chins with remarkable efficacy

23 Mar 2024 by

Injections with polidocanol (10XB-101) help dissolve the pocket of excess fat under the chin, with a faster onset of action and fewer side effects relative to synthetic deoxycholic acid compound (ATX-101) injections, according to the results of a phase IIb study.

Injectable polidocanol targets double chins with remarkable efficacy

23 Mar 2024

Is ChatGPT as good as dermatologists in counselling patients?

22 Mar 2024 by

Use of Chat Generated Pretrained Transformer (ChatGPT), a free artificial intelligence (AI)-based natural language processing tool, to answer dermatologic questions falls short of expectations, according to a study presented at AAD 2024. Responses by doctors are still preferable to ChatGPT-generated answers.

Is ChatGPT as good as dermatologists in counselling patients?

22 Mar 2024

ESK-001 makes good STRIDEs for plaque psoriasis

22 Mar 2024 by

In the phase II dose-ranging STRIDE trial presented at AAD 2024, ESK-001, a highly-selective and potentially best-in-class allosteric tyrosine kinase 2 (TYK2) inhibitor, demonstrated favourable efficacy and safety signals for the treatment of adults with moderate-to-severe plaque psoriasis.

ESK-001 makes good STRIDEs for plaque psoriasis

22 Mar 2024

[MK TEST DO NOT TOUCH] Delgocitinib cream a win for adults with chronic hand eczema

22 Mar 2024 by

Twice-daily application of delgocitinib cream, a topical pan-Janus kinase inhibitor, works for adults with moderate-to-severe chronic hand eczema (CHE) compared with a vehicle cream, according to the pooled analysis of the phase III DELTA-1 and -2 trials presented at AAD 2024.

[MK TEST DO NOT TOUCH] Delgocitinib cream a win for adults with chronic hand eczema

22 Mar 2024